CrownBio Launches an Innovative Grant Program

Funding Advancements in Preclinical Oncology Research

21-Nov-2017 - Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research ...

Crown Bioscience Acquires Molecular Response’s Patient Derived Xenograft (PDX) Business

18-Feb-2015 - Crown Bioscience, Inc. has announced the acquisition of Molecular Response’s PDX models and PDX service operations. The acquisition reinforces Crown’s on-going strategy to be the leading global provider of Translational Oncology services with facilities in Asia, the USA and Europe.Crown is ...

Crown Bioscience Expands Operations

Existing Facility will become Centre of Excellence for Hormonal Oncology and Step up European Operations

12-Jan-2015 - Crown Bioscience, Inc. has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd. (Crown UK). In addition, it was announced that Mike Prosser, Executive Director at Crown ...

Crown Bioscience Announces U.S. Expansion With New Translational Oncology Center

23-Oct-2014 - Crown Bioscience, Inc. has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown.The ...